The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Developed with NVIDIA, the platform also demonstrated high success in designing antimicrobial peptides targeting multidrug-resistant pathogens
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.